We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific Wins CE Mark for Vercise Gevia DBS System (revised)
Read MoreHide Full Article
Medical device major Boston Scientific Corporation (BSX - Free Report) recently won CE mark for its Vercise Gevia Deep Brain Stimulation (DBS) System. It is a rechargeable, magnetic resonance (MR) conditional device for treatment of movement disorder symptoms in Parkinson's disease, dystonia and essential tremor patients.
Generally, DBS therapy is a surgical procedure of placing a device that stimulates specific areas in the brain using electrical signals.
The new DBS system consists of Vercise Neural Navigator 2 with STIMVIEW Technology, allowing clinicians to visualize the stimulation field while planning DBS stimulation programs for patients.
Meanwhile, over the last three months, Boston Scientific has been trading above the Zacks categorized Medical - Products industry. As per the latest share price movement, the company has gained 12.2%, compared to 7% gain of the broader industry. We expect the growing adoption of Boston Vercise DBS system in Europe (not in the U.S. at this time) to enhance the company’s Neuromodulation business prospects and boost its share price.
Notably, the latest CE mark expands Boston Scientific’s Vercise Directional portfolio which is composed of the Vercise Primary Cell (PC) and Vercise Gevia platforms with Vercise Cartesia Directional Lead. The Vercise Directional offerings are considered to be the only DBS solutions that help in delivering accurate stimulation therapy to the neural target for avoiding side effects and obtaining optimal outcomes.
Management claimed that Boston Scientific was the first to bring an eight contact rechargeable platform offering 25 years of durability five years ago. This was followed by the launch of the first directional lead powered by a small primary cell device. The latest Vercise Gevia System also has the advantage of an unparalleled 25-year battery life.
As per a Transparency Market Research report, the global DBS market is projected to reach a value of $3.21 billion by 2020 at a CAGR of 8.9%. This growing trend is primarily based on the increasing number of people suffering from neurological diseases across all age population. Neurological movement disorders such as Parkinson's disease affects nearly 10 million people while Dystonia affects nearly 72 million people globally and is diagnosed more in women.
Zacks Rank & Key Picks
Boston Scientific currently carries a Zacks Rank #3 (Hold). Better-ranked medical stocks include Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Notably, Align Technologyand Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology has an expected long-term adjusted earnings growth of almost 22.8%. The stock added roughly 44.1% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 79.9%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock added roughly 13.1% over the last three months.
(We are reissuing this article to correct a mistake. The original article, issued earlier today, June 7, 2017, should no longer be relied upon.)
3 Stocks to Ride a 588% Revenue Explosion
At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...
By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. See Zacks' Top 3 Stocks to Ride This Space >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Boston Scientific Wins CE Mark for Vercise Gevia DBS System (revised)
Medical device major Boston Scientific Corporation (BSX - Free Report) recently won CE mark for its Vercise Gevia Deep Brain Stimulation (DBS) System. It is a rechargeable, magnetic resonance (MR) conditional device for treatment of movement disorder symptoms in Parkinson's disease, dystonia and essential tremor patients.
Generally, DBS therapy is a surgical procedure of placing a device that stimulates specific areas in the brain using electrical signals.
The new DBS system consists of Vercise Neural Navigator 2 with STIMVIEW Technology, allowing clinicians to visualize the stimulation field while planning DBS stimulation programs for patients.
Meanwhile, over the last three months, Boston Scientific has been trading above the Zacks categorized Medical - Products industry. As per the latest share price movement, the company has gained 12.2%, compared to 7% gain of the broader industry. We expect the growing adoption of Boston Vercise DBS system in Europe (not in the U.S. at this time) to enhance the company’s Neuromodulation business prospects and boost its share price.
Notably, the latest CE mark expands Boston Scientific’s Vercise Directional portfolio which is composed of the Vercise Primary Cell (PC) and Vercise Gevia platforms with Vercise Cartesia Directional Lead. The Vercise Directional offerings are considered to be the only DBS solutions that help in delivering accurate stimulation therapy to the neural target for avoiding side effects and obtaining optimal outcomes.
Management claimed that Boston Scientific was the first to bring an eight contact rechargeable platform offering 25 years of durability five years ago. This was followed by the launch of the first directional lead powered by a small primary cell device. The latest Vercise Gevia System also has the advantage of an unparalleled 25-year battery life.
As per a Transparency Market Research report, the global DBS market is projected to reach a value of $3.21 billion by 2020 at a CAGR of 8.9%. This growing trend is primarily based on the increasing number of people suffering from neurological diseases across all age population. Neurological movement disorders such as Parkinson's disease affects nearly 10 million people while Dystonia affects nearly 72 million people globally and is diagnosed more in women.
Zacks Rank & Key Picks
Boston Scientific currently carries a Zacks Rank #3 (Hold). Better-ranked medical stocks include Align Technology, Inc. (ALGN - Free Report) , Inogen, Inc. (INGN - Free Report) and Accelerate Diagnostics, Inc. (AXDX - Free Report) . Notably, Align Technologyand Inogen sport a Zacks Rank #1 (Strong Buy), while Accelerate Diagnostics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Align Technology has an expected long-term adjusted earnings growth of almost 22.8%. The stock added roughly 44.1% over the last three months.
Inogen has a long-term expected earnings growth rate of 17.5%. The stock has a solid one-year return of around 79.9%.
Accelerate Diagnostics has an expected long-term adjusted earnings growth of 30%. The stock added roughly 13.1% over the last three months.
(We are reissuing this article to correct a mistake. The original article, issued earlier today, June 7, 2017, should no longer be relied upon.)
3 Stocks to Ride a 588% Revenue Explosion
At Zacks, we're mostly focused on short-term profit cycles, but the hottest of all technology mega-trends is starting to take hold...
By last year, it was already generating $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for those who make the right trades early. See Zacks' Top 3 Stocks to Ride This Space >>